Telomerase inhibition is a specific early event in salvicine-treated human lung adenocarcinoma A549 cells
文献类型：期刊论文
| 作者 | Liu, WJ; Zhang, YW; Shen, Y; Jiang, JF; Miao, ZH; Ding, J
|
| 刊名 | BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
 |
| 出版日期 | 2004-10-15 |
| 卷号 | 323期号:2页码:660-667 |
| ISSN号 | 0006-291X |
| 关键词 | salvicine antineoplastic agents telomerase telomere A549 cells |
| DOI | 10.1016/j.bbrc.2004.08.135 |
| 文献子类 | Article |
| 英文摘要 | The telomere and telomerase have been suggested as targets for anticancer drug discovery. However, the mechanisms by which conventional anticancer drugs affect these targets are currently unclear. The novel topoisomerase II inhibitor, salvicine, suppresses telomerase activity in leukemia HL-60 cells. To further determine whether this activity of salvicine is specific to the hematological tumor and distinct from those of other conventional anticancer agents, we studied its effects on telomere and telomerase in a solid lung carcinoma cell line, A549. Differences in telomerase inhibition and telomere erosion were observed between salvcine and other anticancer agents. All anticancer agents (except adriamycin) induced shortening of the telomere, which was identified independent of replication, but only salvicine inhibited telomerase activity in A549 cells under conditions of high concentration and short-term exposure. At the low concentration and long-term exposure mode, all the tested anticancer agents shortened the telomere and inhibited telomerase activity in the same cell line. Notably, salvicine inhibited telomerase activity more severely than the other agents examined. Moreover, the compound inhibited telomerase activity in A549 cells indirectly in a concentration- and time-dependent manner. Salvicine did not affect the expression of hTERT, hTP1, and hTR mRNA in A549 cells following 4 h of exposure. Okadaic acid protected telomerase from inhibition by salvicine. These results indicate specificity of salvicine and diversity of anticancer agents in the mechanism of interference with telomerase and the telomere system. Our data should be helpful for designing the study in the development of agents acting on telomere and/or telomerase. (C) 2004 Elsevier Inc. All rights reserved. |
| WOS关键词 | DNA TOPOISOMERASE-II ; CANCER-CELLS ; IN-VITRO ; ANTICANCER AGENTS ; DOWN-REGULATION ; CYTOTOXICITY ; EXPRESSION ; INDICATOR ; APOPTOSIS ; THERAPY |
| WOS研究方向 | Biochemistry & Molecular Biology ; Biophysics |
| 语种 | 英语 |
| 出版者 | ACADEMIC PRESS INC ELSEVIER SCIENCE |
| WOS记录号 | WOS:000224076900042 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/274005]  |
| 专题 | 药理学第一研究室 中科院受体结构与功能重点实验室 新药研究国家重点实验室 |
| 通讯作者 | Ding, J |
| 作者单位 | Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai Inst Mat Med, State Key Lab Drug Res,Div Antitumor Pharmacol, Shanghai 201203, Peoples R China |
| 推荐引用方式 GB/T 7714 | Liu, WJ,Zhang, YW,Shen, Y,et al. Telomerase inhibition is a specific early event in salvicine-treated human lung adenocarcinoma A549 cells[J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS,2004,323(2):660-667. |
| APA | Liu, WJ,Zhang, YW,Shen, Y,Jiang, JF,Miao, ZH,&Ding, J.(2004).Telomerase inhibition is a specific early event in salvicine-treated human lung adenocarcinoma A549 cells.BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS,323(2),660-667. |
| MLA | Liu, WJ,et al."Telomerase inhibition is a specific early event in salvicine-treated human lung adenocarcinoma A549 cells".BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 323.2(2004):660-667. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。